Merrimack Pharmaceuticals IncNASDAQ:MACK
- LAST PRICE15.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots8.7000/ 2
- Ask / Lots15.1800/ 10
- Open / Previous Close0.0000 / 15.0400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MACK |
|---|---|---|
| 09:32 ET | 6173 | 15.015 |
| 09:38 ET | 300 | 15.015 |
| 09:39 ET | 400 | 15.015 |
| 09:41 ET | 200 | 15.01 |
| 09:43 ET | 1593 | 15.02 |
| 09:50 ET | 600 | 15.01 |
| 09:52 ET | 1300 | 15.02 |
| 09:54 ET | 1600 | 15.02 |
| 09:59 ET | 100 | 15.02 |
| 10:03 ET | 2090 | 15.02 |
| 10:08 ET | 3098 | 15.02 |
| 10:10 ET | 10308 | 15.02 |
| 10:14 ET | 3631 | 15.02 |
| 10:21 ET | 500 | 15.02 |
| 10:30 ET | 376 | 15.02 |
| 10:35 ET | 192 | 15.026 |
| 10:39 ET | 100 | 15.025 |
| 10:51 ET | 2703 | 15.03 |
| 11:02 ET | 400 | 15.03 |
| 11:08 ET | 600 | 15.03 |
| 11:09 ET | 400 | 15.03 |
| 11:11 ET | 980 | 15.03 |
| 11:13 ET | 7173 | 15.03 |
| 11:15 ET | 6773 | 15.03 |
| 11:20 ET | 700 | 15.04 |
| 11:22 ET | 100 | 15.035 |
| 11:26 ET | 983 | 15.04 |
| 11:27 ET | 1500 | 15.03 |
| 11:33 ET | 2402 | 15.03 |
| 11:36 ET | 300 | 15.03 |
| 11:38 ET | 300 | 15.03 |
| 11:40 ET | 26128 | 15.042 |
| 11:42 ET | 200 | 15.05 |
| 11:44 ET | 1000 | 15.05 |
| 11:45 ET | 3200 | 15.05 |
| 11:47 ET | 2710 | 15.06 |
| 11:51 ET | 1900 | 15.055 |
| 12:03 ET | 1600 | 15.055 |
| 12:05 ET | 200 | 15.05 |
| 12:07 ET | 10001 | 15.05 |
| 12:16 ET | 1200 | 15.0536 |
| 12:21 ET | 1300 | 15.05 |
| 12:23 ET | 200 | 15.05 |
| 12:45 ET | 100 | 15.04 |
| 12:48 ET | 100 | 15.05 |
| 12:59 ET | 688 | 15.05 |
| 01:08 ET | 400 | 15.045 |
| 01:17 ET | 100 | 15.05 |
| 01:28 ET | 200 | 15.06 |
| 01:32 ET | 100 | 15.05 |
| 01:53 ET | 100 | 15.05 |
| 02:00 ET | 4996 | 15.05 |
| 02:04 ET | 100 | 15.05 |
| 02:15 ET | 3569 | 15.035 |
| 02:18 ET | 100 | 15.04 |
| 02:20 ET | 100 | 15.0312 |
| 02:26 ET | 100 | 15.035 |
| 02:27 ET | 100 | 15.035 |
| 02:33 ET | 200 | 15.03 |
| 02:38 ET | 200 | 15.03 |
| 02:40 ET | 100 | 15.03 |
| 02:42 ET | 100 | 15.035 |
| 02:44 ET | 400 | 15.03 |
| 02:45 ET | 200 | 15.03 |
| 02:49 ET | 100 | 15.0375 |
| 02:51 ET | 300 | 15.03 |
| 02:58 ET | 1832 | 15.03 |
| 03:02 ET | 700 | 15.035 |
| 03:03 ET | 300 | 15.035 |
| 03:09 ET | 200 | 15.035 |
| 03:16 ET | 100 | 15.035 |
| 03:18 ET | 800 | 15.03 |
| 03:20 ET | 100 | 15.035 |
| 03:21 ET | 100 | 15.035 |
| 03:23 ET | 100 | 15.035 |
| 03:25 ET | 100 | 15.04 |
| 03:27 ET | 100 | 15.035 |
| 03:34 ET | 100 | 15.035 |
| 03:36 ET | 100 | 15.0331 |
| 03:38 ET | 100 | 15.035 |
| 03:39 ET | 100 | 15.04 |
| 03:41 ET | 300 | 15.035 |
| 03:43 ET | 258 | 15.035 |
| 03:45 ET | 100 | 15.035 |
| 03:48 ET | 659 | 15.035 |
| 03:50 ET | 100 | 15.035 |
| 03:52 ET | 200 | 15.035 |
| 03:54 ET | 200 | 15.035 |
| 03:56 ET | 8435 | 15.03 |
| 03:57 ET | 16829 | 15.04 |
| 03:59 ET | 14441 | 15.04 |
Apr 30, 2024
DJ Merrimack Pharma Plans to Delist, Pending Holder Approval of Liquidation Plan, from 6:00PM ET on Tuesday Apr 30, 2024 by Dow Jones
6:00PM ET on Tuesday Apr 30, 2024 by Dow JonesMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution, from 5:15PM ET on Tuesday Apr 30, 2024 by Dow Jones
5:15PM ET on Tuesday Apr 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Merrimack Pharmaceuticals Inc | 218.6M | -182.1x | --- |
INmune Bio Inc | 220.9M | -6.7x | --- |
Boundless Bio Inc | 222.4M | -4.5x | --- |
Renovaro Inc | 214.1M | -2.2x | --- |
Atossa Therapeutics Inc | 213.0M | -7.1x | --- |
Omeros Corp | 210.9M | -1.3x | --- |
Company Information
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Contact Information
- Headquarters
- One Broadway, 14Th FloorCAMBRIDGE, MA, United States 02142
- Phone
- 617-441-1000
- Fax
- 617-491-1386
Executives
- Chairman of the Board, President, Treasurer
- Gary Crocker
- Independent Director
- Eric Andersen
- Independent Director
- Noah Levy
- Independent Director
- Ulrik Nielsen
- Independent Director
- Ana Radeljevic
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $218.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-0.08 |
Book Value | $1.31 |
P/E Ratio | -182.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
